RxDoctor Payments Data

Rabe Alhurani, MD

Geriatric Medicine · Victorville, CANPI 1740778398

Payments from drug & device makers

$925in general payments, 2019–2025

Across 43 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$244
  • Medtronic$121
  • AstraZeneca$96
  • Pfizer$96
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$72
  • Lilly USA, LLC$53
  • plus $243 from 10 others

What the payments were for

  • Food & beverage$925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$925 in reported general payments places this provider in the 75th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$141,164
Medicare patients
283
Services billed
1,202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$107,301
EliquisApixaban69$68,774
XareltoRivaroxaban36$40,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,212
JardianceEmpagliflozin25$24,475
JanuviaSitagliptin Phosphate22$22,978
EntrestoSacubitril/Valsartan14$22,148
RybelsusSemaglutide14$19,356
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$12,713
Albuterol Sulfate HfaAlbuterol Sulfate114$4,022
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$3,638
Gabapentin141$3,375
Atorvastatin Calcium392$3,085
LantusInsulin Glargine,hum.Rec.Anlog34$3,048
Levothyroxine Sodium217$2,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$244$126,657120 claims
PfizerEliquis$96$68,77469 claims
Johnson & JohnsonXarelto$16$40,78936 claims
Boehringer IngelheimJardiance$51$24,47525 claims
MerckJanuvia$24$22,97822 claims
NovartisEntresto$21$22,14814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →